QuanDx is an innovation leader in molecular diagnostics. Specializing in the development and commercialization of novel diagnostic tools, QuanDx’s products deliver personalized medicine to clinical and research laboratories worldwide.

QuanDx’s patented Yin-Yang Probe technology combines cutting-edge technology with ease of use to provide the best available diagnostic and prognostic information for hematological and solid tumor cancers, as well as a number of infectious diseases.

In addition to its proprietary diagnostics line, QuanDx offers state-of-the-art instruments for PCR applications and nucleic acid extraction.

Our History

Founded in 2012, QuanDx was launched with a vision to develop and commercialize innovative and unique diagnostic assays that could be used in clinical and research laboratories worldwide. Since then, QuanDx has grown quickly, and has delivered on the promise of personalized medicine through the development and launch of cutting-edge diagnostic technologies that are faster, simpler, and more cost-effective than other tests on the market.

QuanDx is located in San Jose (San Francisco Bay Area), California, where the company benefits from being in the heart of the Bay Area’s biotech industry.

To date, QuanDx has built a diverse portfolio of tests for hematological and solid tumor cancers, including leukemia, and lung cancer. The company also offers unique testing capabilities for infectious diseases including HPV.